​

Milestone Pharmaceuticals Stock (NASDAQ:MIST)

ForecastOwnershipFinancialsChart

Previous Close

$1.98

52W Range

$1.12 - $2.40

50D Avg

$1.73

200D Avg

$1.58

Market Cap

$114.65M

Avg Vol (3M)

$351.95K

Beta

1.73

Div Yield

-

MIST Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

47

IPO Date

May 09, 2019

Website

MIST Performance

MIST Financial Summary

Dec 23Dec 22Dec 21
Revenue$1.00M$5.00M$15.00M
Operating Income$-61.41M$-59.64M$-43.07M
Net Income$-59.69M$-57.13M$-42.63M
EBITDA$-60.81M$-59.64M$-42.98M
Basic EPS$-1.39$-1.35$-1.02
Diluted EPS$-1.39$-1.35$-1.02

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
BOLTBolt Biotherapeutics, Inc.
IVAInventiva S.A.
IKTInhibikase Therapeutics, Inc.
ONCYOncolytics Biotech Inc.
SCPHscPharmaceuticals Inc.
CMPXCompass Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
XFORX4 Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
DMACDiaMedica Therapeutics Inc.
NAMSNewAmsterdam Pharma Company N.V.
CHRSCoherus BioSciences, Inc.
MCRBSeres Therapeutics, Inc.
HOOKHOOKIPA Pharma Inc.
CGEMCullinan Oncology, Inc.
SPROSpero Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.